Zap Surgical raises $11M Series E from Chinese pharma backers

What's the deal? Zap Surgical Systems, a US developer of radiosurgery equipment, has raised US$10.2M in a Series E round. Baheal PharmaceuticalDealroom has a profile for this one. Try Dealroom → and Baiyang PharmaceuticalDealroom has a profile for this one. Try Dealroom → backed the round, announced in September 2026.

The details: Baiyang Pharmaceutical disclosed on September 22 that it subscribed to 15,214,385 Series E-1 preferred shares at $0.723 per share. After the deal, it holds an indirect 20.86% stake in Zap Surgical.

What's the endgame? Zap Surgical's core product is the ZAP-X radiosurgery robot, built for non-invasive, precise radiation therapy of brain and head-and-neck tumours.

The signal: The investment deepens Chinese pharmaceutical firms' ties to US medical-device makers, pairing overseas surgical technology with domestic distribution reach.

Image credit: NavyMedicine